- Conditions
- Crohn's Disease
- Interventions
- Brazikumab IV Infusion, Brazikumab SC Injection, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Lone Tree, Colorado • Clearwater, Florida + 25 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 97
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Moderately to Severely Active Crohns Disease
- Interventions
- Afimkibart, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 95
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Sun City, Arizona + 79 more
- Conditions
- Crohn's Disease
- Interventions
- placebo for risankizumab IV, risankizumab SC, risankizumab IV
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 618 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 114
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 89 more
- Conditions
- Ulcerative Colitis (UC), Crohn's Disease
- Interventions
- Risankizumab, Cytochrome P450 (CYP) Substrates
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 4
- States / cities
- Coronado, California • DeLand, Florida • Margate, Florida + 1 more
- Conditions
- Crohn Disease
- Interventions
- LY4395089, Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Oxnard, California + 11 more
- Conditions
- Crohn's Disease, Inflammatory Bowel Disease, IBD, Colitis
- Interventions
- Group 1: Placebo, Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 640 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 84
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 81 more
- Conditions
- Crohns Disease
- Interventions
- Afimkibart
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 5
- States / cities
- Dothan, Alabama • Hamden, Connecticut • Kissimmee, Florida + 2 more
- Conditions
- Crohn's Disease, IBD
- Interventions
- Brazikumab Induction Dose, Brazikumab Maintenance Dose
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 10
- States / cities
- Lincoln, California • Clearwater, Florida • Kissimmee, Florida + 6 more
- Conditions
- Crohn's Disease
- Interventions
- placebo for risankizumab, risankizumab IV, risankizumab SC
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 931 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 117
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 94 more
- Conditions
- Crohn's Disease
- Interventions
- natalizumab
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Hartford, Connecticut • Miami, Florida + 7 more
- Conditions
- Colitis, Ulcerative, Crohn Disease
- Interventions
- Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC), LY4395089
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Oxnard, California + 11 more
- Conditions
- Crohn's Disease
- Interventions
- 683699
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 13
- States / cities
- Garden Grove, California • Roseville, California • Miami, Florida + 10 more
- Conditions
- Crohn's Disease
- Interventions
- Vedolizumab, Upadacitinib, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 19
- States / cities
- La Jolla, California • Los Angeles, California • Colorado Springs, Colorado + 12 more
- Conditions
- Inflammatory Bowel Diseases, Crohn's Disease
- Interventions
- Placebo, MORF-057
- Drug
- Lead sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 385 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 25
- States / cities
- Lancaster, California • San Diego, California • Colorado Springs, Colorado + 21 more
- Conditions
- Crohn Disease
- Interventions
- JNJ-78934804, Guselkumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 20
- States / cities
- Anaheim, California • Chula Vista, California • Los Alamitos, California + 17 more
- Conditions
- Crohn's Disease (CD)
- Interventions
- Vedolizumab IV
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Diego, California + 19 more
- Conditions
- Moderately to Severely Active Crohns Disease
- Interventions
- Afimkibart, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 425 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 61
- States / cities
- Dothan, Alabama • Glendale, Arizona • Lancaster, California + 55 more
- Conditions
- Crohn Disease
- Interventions
- Guselkumab, Risankizumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 39
- States / cities
- Dothan, Alabama • Mobile, Alabama • Anaheim, California + 32 more
- Conditions
- Crohn's Disease
- Interventions
- Duvakitug, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 751 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 34
- States / cities
- Colorado Springs, Colorado • Kissimmee, Florida • Miami, Florida + 26 more
- Conditions
- Crohn's Disease
- Interventions
- Vedolizumab SC 108 mg, Placebo, Vedolizumab IV 300 mg
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 644 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Hamden, Connecticut • Middletown, Connecticut + 27 more
- Conditions
- Crohn's Disease
- Interventions
- Trichuris suis ova (TSO), Placebo
- Biological
- Lead sponsor
- Coronado Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 73
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 64 more
- Conditions
- Crohn Disease
- Interventions
- Placebo for Ustekinumab, Placebo for Adalimumab, Ustekinumab (6 mg/kg), Ustekinumab (90 mg), Adalimumab (40 mg)
- Biological
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 67
- States / cities
- Mobile, Alabama • San Diego, California • Colorado Springs, Colorado + 60 more
- Conditions
- Crohn's Disease
- Interventions
- Mirikizumab, Ustekinumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 15 Years to 80 Years
- Enrollment
- 1,158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 140
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 113 more
- Conditions
- Ulcerative Colitis, Crohn's Disease
- Interventions
- Vedolizumab IV, Vedolizumab SC
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 100
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 88 more